• Journal of the korean veterinary medical association
• /
• v.22 no.6
• /
• pp.353-356
• /
• 1986

• Journal of the korean veterinary medical association
• /
• v.20 no.10
• /
• pp.622-630
• /
• 1984

• Journal of the korean veterinary medical association
• /
• v.45 no.2
• /
• pp.159-163
• /
• 2009

• Journal of the korean veterinary medical association
• /
• v.20 no.5
• /
• pp.271-278
• /
• 1984

• Journal of Veterinary Clinics
• /
• v.31 no.5
• /
• pp.361-366
• /
• 2014

The aim of this study was to determine if vaccines containing CPV-2 or CPV-2b provided protection against challenge with a recent Korean CPV-2a isolate. Twenty mongrel pups aged 9 weeks old were used. The commercial CPV-2 or CPV-2b vaccines were administered to each of the 8 pups thrice every 3 weeks, respectively. Two weeks after the last vaccination, all pups were challenged with CPV-2a (VR00174 strain) $1{\times}10^6\;TCID_{50}$. Clinical signs, fecal excretion of challenged CPV, and serological response of pups were observed for 2 weeks after challenge. All vaccinated pups did not display any clinical signs of disease after challenge with Korean CPV-2a isolate, whereas all non-vaccinated pups exhibited mucoid or hemorrhagic diarrhea, vomiting and anorexia. In all non-vaccinated pups, the virus could be detected in feces from 4 days after challenge, whereas in vaccinated pups, no evidence of viral excretion could be detected. Two of 4 non-vaccinated pups died 6 days after the challenge. This study showed that the two commercial CPV-2 and CPV-2b vaccines were effective in preventing infection and/or disease caused by the Korean CPV-2a isolate.